Altered calcium influx of peripheral Th2 cells in pediatric Crohn's disease: Infliximab may normalize activation patterns

Csaba Orbán, Dolóresz Szabó, Anna Bajnok, B. Vásárhelyi, T. Tulassay, A. Arató, G. Veres, Gergely Toldi

Research output: Contribution to journalArticle

1 Citation (Scopus)


Objective: Crohn's disease is a chronic inflammation of the gastrointestinal tract with an abnormal immune phenotype. We investigated how intracellular calcium kinetics of Th1 and Th2 lymphocytes alter upon specific inhibition of Kv1.3 and IKCa1 channels in pediatric Crohn's disease. Study design: Blood was taken from 12 healthy and 29 Crohn's disease children. Of those, 6 were switched to infliximab and re-sampled after the 4th infliximab treatment. Intracellular calcium levels were monitored using flow cytometry in the presence or absence of specific inhibitors of Kv1.3 and IKCa1 potassium channels. Results: In Crohn's disease treated with standard therapy, calcium response during activation was higher than normal in Th2 cells. This was normalized in vitro by inhibition of Kv1.3 or IKCa1 potassium channels. After the switch to infliximab, potassium channel function and expression in Th2 lymphocytes were comparable to those in Th1 cells. Conclusion: These results may indicate that potassium channels are potential immune modulatory targets in Crohn's disease.

Original languageEnglish
Pages (from-to)44966-44974
Number of pages9
Issue number29
Publication statusPublished - 2016



  • Crohn's disease
  • IKCa1
  • Immune response
  • Immunity
  • Immunology and Microbiology Section
  • Infliximab
  • Kv1.3
  • Th2

ASJC Scopus subject areas

  • Oncology

Cite this